Vertex Pharmaceuticals

To see an up-to date selection of historical analyses and insights on Vertex Pharmaceuticals, visit our new, dynamically updated Company Summary report pages for Vertex Pharmaceuticals.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for Vertex Pharmaceuticals are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Vertex Pharmaceuticals, or on any other Company covered by EvaluatePharma® Contact Us today.

NEWS - Selected Product News Headlines (as of 11 June 2008)
Vertex Announces Results from Phase 2a Trial of VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosis   (Vertex Pharmaceuticals)   (Invalid Date)
Vertex Reviews 2010 Business Priorities to Support Goal of Becoming Fully-Capable Biopharmaceutical Company   (Vertex Pharmaceuticals)   (Invalid Date)
Vertex shows that less is definitely more with hep C data   (Vertex Pharmaceuticals)   (Invalid Date)
More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens   (Vertex Pharmaceuticals)   (Invalid Date)
More Than 80 Percent of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response With Twice-Daily Telaprevir-Based Regimen   (Johnson & Johnson)   (Invalid Date)
Event - Vertex, Schering-Plough line up hep C data as pivotal results loom   (Vertex Pharmaceuticals)   (Invalid Date)
Interim Results from Study 107 Highlight the Potential Role of Telaprevir-Based Regimens in HCV Patients Who Failed Prior Treatment   (Vertex Pharmaceuticals)   (Invalid Date)
Vertex Pharmaceuticals Provides Corporate Update   (Vertex Pharmaceuticals)   (Invalid Date)
Vertex Pharmaceuticals Announces Publication of Telaprevir Abstracts for Presentation at the 60th AASLD Meeting   (Vertex Pharmaceuticals)   (Invalid Date)
Vertex's novel financing causes intrigue   (Vertex Pharmaceuticals)   (Invalid Date)
Vertex Pharmaceuticals Initiates Phase 3 Registration Program for VX-770, an Oral CFTR Potentiator Targeting the Defective Protein Responsible for Cystic Fibrosis   (Vertex Pharmaceuticals)   (Invalid Date)
New England Journal of Medicine Publishes Landmark Clinical Studies of the Investigational Hepatitis C Virus Protease Inhibitor Telaprevir   (Vertex Pharmaceuticals)   (Invalid Date)
Telaprevir Data Presented at EASL Show Unprcedented SVR Rates in HCV Treatment-Failure Patients in PROVE 3 Study   (Vertex Pharmaceuticals)   (Invalid Date)
New Data On Tibotec Investigational Hepatitis C Compounds Being Presented At EASL   (Johnson & Johnson)   (Invalid Date)
Vertex Pharmaceuticals to Present Data at EASL Suggesting Telaprevir's Potential for Use in a Broad Range of HCV Patients and Highlighting the Company's Expanded STAT-C Portfolio   (Vertex Pharmaceuticals)   (Invalid Date)
Vertex Pharmaceuticals Initiates Phase 2 Development for CFTR Corrector VX-809 in Patients with Cystic Fibrosis   (Vertex Pharmaceuticals)   (Invalid Date)
Vertex strengthens hold on hepatitis C field   (Vertex Pharmaceuticals)   (Invalid Date)
Vertex Pharmaceuticals Strengthens HCV Drug Development Portfolio, Adds Novel Polymerase Inhibitors to Shape New Combinations with Telaprevir   (Vertex Pharmaceuticals)   (Invalid Date)

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.